In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC.

Guests:
Kelsey Pan, MD, MPH
Assistant Professor of Medicine
Department of Hematology & Oncology, Thoracic Medical Oncology Section
Emory University Winship Cancer Institute

Rajat Thawani, MD
Assistant Professor of Medicine
Division of Hematology and Oncology
Knight Cancer Institute, OHSU